Supplementary Online Content

Similar documents
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Pharmacologic Agents for Treatment of Type 2 Diabetes

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Oral and Injectable Medication Options for Diabetes Treatment

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

How to Fight Diabetes and Win. Diabetes. Medications

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Index. Note: Page numbers of article titles are in boldface type.

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Supplementary Online Content

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine

New Measure Recommended for Endorsement by PQA

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education

Diabetes Medications: Oral Anti-Hyperglycemic Medications

What s New on the Horizon: Diabetes Medication Update

Drugs used in Diabetes. Dr Andrew Smith

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Diabetes Management: A diagnostic perspective

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Wayne Gravois, MD August 6, 2017

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville

第十五章. Diabetes Mellitus

Type. Diabetes Drugs. A Review

Diabetes Treatment Update

Diabetes Basics. Type 1 diabetes The body cannot make insulin Requires insulin injection Is not treated with oral diabetes medicines (pills)

I. General Considerations

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

Cardiovascular Health and Diabetes Screening for People with Schizophrenia

What s New in Diabetes Medications. Jena Torpin, PharmD

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control

Supplementary Online Content

Physiology of Normoglycemia

Hypoglycemia, diabetic medications

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

Initiating Injectable Therapy in Type 2 Diabetes

CADTH Optimal use report

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Making Sense of Mediations for Diabetes

Type 2 Diabetes Mellitus 2011

The Community Pharmacist s Role in Diabetes Treatment

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 Diabetes Mellitus Insulin Therapy 2012

Starting insulin in patients with type 2 diabetes: An individualized approach

Information for Patients

Understanding Diabetes and Insulin Delivery Systems

AACN PCCN Review. Endocrine

Patient With Implantable Cardiac Device (ICD)

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18

Insulin Prior Authorization with optional Quantity Limit Program Summary

CE on SUNDAY Miami, FL May 31, 2009

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Diabetes Treatment Guidelines

Pancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Collaborative Practice Agreement

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Drug Class Review Newer Diabetes Medications and Combinations

CURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.

Indiana Medicaid Drug Utilization Review Board Newsletter

Antidiabetic Agents CHAPTER BIGUANIDES

Diabetes Treatment Data Points #9

DIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013

Advanced Practice Education Associates. Endocrine

Glucose Control drug treatments

What s New in Diabetes Treatment. Disclosures

Hypoglyceamia and Exercise

Pharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

Update on Diabetes Mellitus

Anti-Diabetic. Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin. Exocrine gland that produces digestive enzymes.

DM Fundamentals Class 4 Meds for Type 2

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

Diabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016

Comprehensive Diabetes Treatment

Diabetes Mellitus II CPG

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

DIABETES RESEARCH A CLINICIAN S OVERVIEW

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

The Signs, Symptoms, and Causes of Hypoglycemia

The information in this guide comes from a government-funded review of research about pills for type 2 diabetes.

Cardiovascular Management of a Patient with Diabetes

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth

Endocrine Pharmacology:

FUNDING: MICIS mandated by Maine Legislature, funded by fees collected from pharmaceutical companies as a cost of doing business in the state.

Medical Overview of Diabetes in Older Adults

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Transcription:

Supplementary Online Content Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Internal Medicine. Published online March 10, 2014. doi:10.1001/jamainternmed.2014.136. etable 1. Definitions and examples of data elements utilized in analysis of emergency department visits and emergency hospitalizations for insulin-related hypoglycemia and errors etable 2. Number of cases of emergency department visits for insulin-related hypoglycemia and errors, by additional case characteristics, 2007-2011 This supplementary material has been provided by the authors to give readers additional information about their work.

Hypoglycemia and Errors Data Element Definitions/Examples Comments Location of Event Home Institutional setting While driving (including found in car) Work, school, or place of recreation/sports Outpatient setting eg, patient's home, including adult or youth group home eg, long-term care, mental health facility, assisted living facilities eg, hypoglycemia episode leading to MVA, or hypoglycemic patient found in car" eg, swimming pool, gym, senior center eg, physician office, dialysis center, outpatient surgery center Other public property Clinical Presentation of Event Hypoglycemia With shock, loss of consciousness, or seizure With fall or injury With altered mental status With other neurologic sequelae With presyncope/syncope With other sequelae eg, sidewalk, shopping mall Diagnosis of or treatment for hypoglycemia eg, "Unresponsive to stimuli", "Hypoglycemic seizure", "Loss of consciousness", "Shock hypoglycemic", "Hypoglycemic coma" eg, "Fall", "Road traffic accident", "Head injury", "Laceration", "Contusion", "Fracture" eg, "Mental status changes", "Confusional state", "Depressed level of consciousness", "Lethargy", "Aggression", "Disorientation" eg, "Hyperhidrosis", "Tremor", "Speech disorder", "Fatigue", "Headache" eg, "Dizziness", "Syncope", "Presyncope" eg, "Muscular weakness", "Vomiting", "Nausea", "Malaise", "Dyspnea" Clinical presentations were coded using MedDRA terminology and were categorized in hierarchical and mutually exclusive fashion; eg, a case where a patient fell and had a hypoglycemic seizure is categorized under Hypoglycemia with shock, loss of consciousness, or seizure.

Hypoglycemia and Errors (continued) Documented Diabetes Therapy Insulin Product Types Short-acting Rapid-acting Intermediate-acting Long-acting Regular Aspart, Lispro, Glulisine NPH, Lente Glargine, Detemir Insulin Mix eg, "Mix", "70/30", "75/25" Insulin Inhaled Not documented Other Diabetic agents Oral diabetic agents Injectable diabetic agents eg, "Insulin" not otherwise specified Alpha-glucosidase inhibitors (eg, acarbose, miglitol), Biguanides (metformin), Dipeptidyl peptidase-4 inhibitors/gliptins (eg, saxagliptin, sitagliptin), Meglitinides (eg, nateglinide, repaglinide), Sulfonylureas (eg, glimepiride, glipizide, glyburide), Thiazolidinediones/Glitazones (eg, pioglitazone, rosiglitazone) Amylin analogs (eg, pramlintide), Glucagonlike peptide-1 agonists (eg, exenatide, liraglutide) All narrative and medication fields were searched to identify recorded insulin products and all products were included under Insulin Product Types (etable 2). Insulin product types were assumed to be single agent formulations (eg, "NovoLog") unless specified as mix preparations (eg, "NovoLog 70/30"). Ambiguous insulin mentions (eg, "Humulin", "Novolin") were categorized as "Not documented". All narrative and medication fields were searched to identify recorded diabetic agents other than insulin. Combination oral diabetic agents were categorized separately as their individual components (eg, "Glucovance" is counted under both "Sulfonylureas" and "Biguanides"). Cases where oral diabetes therapy (eg, "diabetes pill") is mentioned, but the agent is not specified were categorized as "Other/unspecified oral agent".

Hypoglycemia and Errors (continued) Blood Glucose, mg/dl (to convert to millimoles per liter, multiply by 0.0555) <40 40-50 51-60 61-70 >70 EMS or ED Treatments Intravenous dextrose Dextrose 50% Glucagon Meal/juice or oral glucose Observation/IV fluids only Other treatment "Too low to read, LLL, L, Lo, Critically low", "Low" were assigned a value of 39.5 mg/dl (to convert to millimoles per liter, multiply by 0.0555). eg, "Meal", "Food Tray", "Glucose" Normal saline, dextrose 5% or 10% in water Octreotide, potassium chloride, sodium bicarbonate All narrative fields were searched for the lowest, pretreatment BG level documented. BG level categories (<40, 40-50, 51-60, 61-70, >70) were chosen to reflect generallyaccepted categories of hypoglycemia. 22 Where it was unclear whether BG level(s) were pre-treatment, the recorded lowest value was coded if either no hypoglycemia treatment was specified in the narrative, or the value recorded was in the hypoglycemic range (ie, 70 mg/dl). Reported ranges (eg, blood glucose in the thirties ) were converted into the lowest decile plus 0.5 mg/dl (eg, BG in the thirties was coded as 30.5 mg/dl); where a less than range was documented, the highest number minus 0.5 mg/dl was used (eg, less than 30 was coded as 29.5 mg/dl). "Not documented" was coded if no BG level(s) were documented in the narrative, if BG level(s) were documented as being subsequent to treatment for hypoglycemia, or if it was unclear whether the BG level(s) were pre- or post-hypoglycemia treatment status and the recorded level(s) were >70 mg/dl. All narrative fields were searched for EMS or ED treatments specific to management of the hypoglycemic episode. Treatments administered by patients, family members, or caregivers were excluded. Treatments were categorized in hierarchical and mutually exclusive fashion; eg, a case

where both glucagon and intravenous fluids were administered was categorized under Glucagon.

Hypoglycemia and Errors (continued) Precipitating Factor Meal-related misadventure Unintentionally took wrong insulin product Unintentionally took wrong dose / confused units Intentionally took "additional" dose Pump-related misadventure Other misadventure Administration of insulin without regard to food intake (eg, neglecting to eat shortly after taking a rapid-acting insulin, not adjusting insulin regimen in the presence of reduced caloric intake due to illness) Accidental administration of the wrong insulin product Accidental administration of the wrong insulin dose Intentional administration of insulin in addition to what is normally administered to the patient Complications specific to pump management (eg, inadvertent bolus when changing pump, pump malfunction) Insulin administration at the incorrect time or without regard to checking blood glucose, administration of "too much insulin" not further described, or medication error with insulin not otherwise specified. All narrative fields were searched for precipitating factors specific to the IHE. Abbreviations: BG, blood glucose; ED, emergency department; EMS, emergency medical services; IHE, insulin-related hypoglycemia and errors; IV, intravenous; MedDRA, Medical Dictionary for Regulatory Activities; MVA, motor vehicle accident.

etable 2. Number of Cases of Emergency Department Visits for Insulin-related Hypoglycemia and Errors, by Additional Case Characteristics, 2007-2011 a ED Visits for IHEs Case Characteristics Cases No. % Location of Event Home 4316 53.3 Institutional setting 573 7.1 While driving (including found in car) 230 2.8 Work, school, or place of recreation/sports 231 2.9 Outpatient setting 72 0.9 Other public property 527 6.5 Not documented 2151 26.6 Insulin Product Types b Short-Acting (Regular) 480 5.9 Rapid-Acting 2138 26.4 Intermediate-Acting 357 4.4 Long-Acting 2663 32.9 Insulin Mix 564 7.0 Not documented 3849 47.5 Blood Glucose, mg/dl (to convert to millimoles per liter, multiply by 0.0555) <40 3140 38.8 40-50 1182 14.6 51-60 525 6.5 61-70 193 2.4 >70 111 1.4 Not documented 2949 36.4 EMS or ED Treatments Intravenous dextrose 50% 4116 50.8 Glucagon 345 4.3 Meal/juice or oral glucose 896 11.1 Observation/IV fluids only 680 8.4 Other treatment 24 0.3 Not documented 2039 25.2 Abbreviations: ED, emergency department; EMS, emergency medical services; IHEs, insulin-related hypoglycemia and errors. a Case counts from the National Electronic Injury Surveillance System - Cooperative Adverse Drug Event Surveillance project, Centers for Disease Control and Prevention. Refer to etable 1 for definitions of case characteristics. b All insulin products reported in the ED medical record, including those implicated in IHEs and those listed as concomitant medications. Not shown: 3 cases of inhaled insulin. Percentages may not total 100% because categories are not mutually exclusive.